Compare 10X Genomics Inc (TXG) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs Verisign, Inc. — how do they compare? 10X Genomics Inc trades at $80.65 (market cap $10.07B), while Verisign, Inc. trades at $303.74 (market cap $26.92B). The key difference: Verisign, Inc. is far larger — about 2.7× 10X Genomics Inc's market cap, and Verisign, Inc. pays a 1.09% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold 10X Genomics Inc for 91 Days and Verisign, Inc. for 123 Days on average.
| TXG | VRSN | |
|---|---|---|
Market Cap | $10.07B | $26.92B |
Volume | 5,657,286 | 1,921,402 |
Sector | Health | Technology |
52-Week High | $97.74 | $310.00 |
52-Week Low | $11.48 | $211.49 |
Typical Hold Time | 91 Days | 123 Days |
Enterprise Value | $9.59B | $28.23B |
Dividend Yield | — | 1.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
10x Genomics (TXG) trades at $77.28, up 1.55% on the day, with a bearish technical signal from moving averages. The company shows improving fundamentals with revenue of $642.82M in 2025 and a reduced net loss of -$43.54M, while recent news highlights strong demand for its Atera spatial biology platform and a patent victory. Positive earnings beats in recent quarters contrast with a high EV/EBITDA of 249.22, indicating significant growth expectations are priced in.
The outlook is mixed; analyst consensus is neutral with a $74.30 price target slightly below the current price, yet operational cash flow turned strongly positive in 2025. Key risks include persistent net losses, high valuation multiples, and execution on new product launches. The stock's near-term direction hinges on Atera's commercial success and achieving profitability.
VeriSign (VRSN) trades at $297.79, up 1.21% today, with a bullish technical signal and strong fundamentals including a 49.77% net income margin. Recent earnings show mixed quarterly beats, while institutional buying and a pending Q3 2026 report highlight investor interest. The stock faces resistance near $299, with support at $296.
Outlook remains positive with a consensus price target of $348, driven by robust cash flow and domain growth, though risks include an antitrust lawsuit and high valuation multiples. The buy-rated stock offers upside potential but requires monitoring of legal and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
